Bristol Myers Squibb is moving aggressively to spotlight its expanding cancer pipeline.
The pharma powerhouse is set to announcr more than 60 data disclosures and 19 oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,” spanning multiple drug classes and experimental approaches.
“This ASCO features the breadth of our oncology pipeline across multiple tumor types and different approaches such as bispecifics, ADCs and targeted therapies, and showcases the potential of our industry-leading CELMoD modality,” said Cristian Massacesi, executive vice president, chief medical officer and head of Development, Bristol Myers Squibb.
“Throughout the meeting, we will also highlight novel combinations that we believe could offer innovative and meaningful options to people with cancer.”
A major focus will be the company’s CELMoD (cereblon E3 ligase modulation) platform, with multiple presentations in multiple myeloma and lymphoma aimed at advancing targeted protein degradation strategies.
Among the highlights is late-breaking Phase 3 data from the SUCCESSOR-2 trial evaluating mezigdomide in combination with carfilzomib and dexamethasone versus standard therapy in relapsed or refractory multiple myeloma, to be presented in an oral session.
Additional results include safety and 12-month efficacy data for golcadomide in combination with pola-RCHP for newly diagnosed aggressive B-cell lymphoma, as well as efficacy and safety data for iberdomide in newly diagnosed multiple myeloma when combined with daratumumab, bortezomib and dexamethasone.
The company will also present a broader slate of oncology programs across breast, gastrointestinal and lung cancers.
In breast and gastrointestinal cancers, attention will turn to izalontamab brengitecan (iza-bren), an EGFRxHER3 antibody-drug conjugate, with Phase 3 data comparing it against chemotherapy in patients with triple-negative breast cancer and esophageal squamous cell carcinoma.
Outside China, iza-bren is being jointly developed by SystImmune and Bristol Myers Squibb.
In lung cancer, the company—together with BioNTech—will present first global Phase 2 data for pumitamig, a PD-L1 x VEGF-A bispecific immunomodulator, in combination with chemotherapy in previously untreated non-small cell lung cancer.
Rounding out the program are updates in cell therapy, including real-world outcomes and healthcare utilization data for CAR T therapies across treatment centers, and early real-world results for Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory blood cancers including chronic lymphocytic leukemia and mantle cell lymphoma.
